Aerial photograph of a green field. PHOTO: UNSPLASH
What Overstory’s vegetation intelligence reveals about wildfire and outage risk.
Updated
November 27, 2025 3:26 PM
Aerial photograph of a green field. PHOTO: UNSPLASH
Managing vegetation around power lines has long been one of the biggest operational challenges for utilities. A single tree growing too close to electrical infrastructure can trigger outages or, in the worst cases, spark fires. With vast service territories, shifting weather patterns and limited visibility into changing landscape conditions, utilities often rely on inspections and broad wildfire-risk maps that provide only partial insight into where the most serious threats actually are.
Overstory, a company specializing in AI-powered vegetation intelligence, addresses this visibility gap with a platform that uses high-resolution satellite imagery and machine-learning models to interpret vegetation conditions in detail.Instead of assessing risk by region, terrain type or outdated maps, the system evaluates conditions tree by tree. This helps utilities identify precisely where hazards exist and which areas demand immediate intervention—critical in regions where small variations in vegetation density, fuel type or moisture levels can influence how quickly a spark might spread.
At the core of this technology is Overstory’s proprietary Fuel Detection Model, designed to identify vegetation most likely to ignite or accelerate wildfire spread. Unlike broad, publicly available fire-risk maps, the model analyzes the specific fuel conditions surrounding electrical infrastructure. By pinpointing exact locations where certain fuel types or densities create elevated risk, utilities can plan targeted wildfire-mitigation work rather than relying on sweeping, resource-heavy maintenance cycles.
This data-driven approach is reshaping how utilities structure vegetation-management programs. Having visibility into where risks are concentrated—and which trees or areas pose the highest threat—allows teams to prioritize work based on measurable evidence. For many utilities, this shift supports more efficient crew deployment, reduces unnecessary trims and builds clearer justification for preventive action. It also offers a path to strengthening grid reliability without expanding operational budgets.
Overstory’s recent US$43 million Series B funding round, led by Blume Equity with support from Energy Impact Partners and existing investors, reflects growing interest in AI tools that translate environmental data into actionable wildfire-prevention intelligence. The investment will support further development of Overstory’s risk models and help expand access to its vegetation-intelligence platform.
Yet the company’s focus remains consistent: giving utilities sharper, real-time visibility into the landscapes they manage. By converting satellite observations into clear and actionable insights, Overstory’s AI system provides a more informed foundation for decisions that impact grid safety and community resilience. In an environment where a single missed hazard can have far-reaching consequences, early and precise detection has become an essential tool for preventing wildfires before they start.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 28, 2025 4:18 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.